CareMed Selected as National Pharmacy Partner for Alzheimer's Drug Leqembi
Key Insights
BrightSpring Health Services (search)' CareMed (search) has been chosen by Eisai as a national specialty pharmacy provider for Leqembi, an Alzheimer's disease (search) treatment.
Clinical trials demonstrated Leqembi's effectiveness in slowing cognitive impairment progression over 18 months in patients with early Alzheimer's.
CareMed (search)'s partnership with Eisai aims to improve patient access to innovative medications and comprehensive support for Alzheimer's treatment.
BrightSpring Health Services (search) (NASDAQ: BTSG) announced that its subsidiary CareMed (search) has been selected by Eisai as a national specialty pharmacy provider for Leqembi (lecanemab), a treatment for Alzheimer's disease (search). This selection highlights CareMed's role in distributing a medication that has demonstrated efficacy in slowing the progression of cognitive impairment associated with early Alzheimer's.
Clinical Trial Results
The FDA approval of Leqembi was based on Phase III clinical trial results involving 1,795 patients aged 50 to 90 with early Alzheimer's disease (search). The study compared Leqembi to placebo, randomizing patients in a 1:1 ratio to receive either intravenous Leqembi or placebo. Results indicated that patients who received Leqembi experienced a slowed progression of cognitive impairment over an 18-month period compared to those on placebo.
Leqembi is a monoclonal antibody designed to target aggregated soluble and insoluble forms of amyloid beta (search), a hallmark of Alzheimer's disease (search). The drug aims to reduce amyloid plaques in the brain, which are thought to contribute to cognitive decline.
Impact and Perspective
"We’re proud of the work CareMed (search) is doing with manufacturers and prescribers to improve and extend the lives of patients living with mild cognitive impairment and dementia, bringing more treatment options to Alzheimer’s disease," said BrightSpring’s President and CEO, Jon Rousseau. He emphasized that CareMed's partnership with Eisai demonstrates a strong commitment to increasing patient access to innovative medications and treatments, while delivering comprehensive support and care to patients and their families.
Benito Fernandez, Chief Commercial Officer at CareMed (search), added, "At CareMed, we’re constantly looking for new opportunities to expand our portfolio of breakthrough treatments and therapies for patients living with devastating diseases. We’re proud to be in the specialty pharmacy network for Leqembi. We’re confident this new medication will help more patients with Alzheimer’s get the right treatment to improve their quality of life."
About CareMed Specialty Pharmacy
CareMed (search) is an independent Specialty Pharmacy and clinical support services company within the BrightSpring enterprise. It focuses on serving the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers involved in chronic and rare disease treatment. CareMed is headquartered in New Hyde Park, New York, and is a flagship specialty pharmacy brand of PharMerica Corporation.